Caffeine in the Prevention of Post-operative Nausea and Vomiting - Full Text View

Purpose

The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.

Condition	Intervention
Postoperative Nausea and Vomiting	Drug: Caffeine


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Care Provider, Investigator, Outcomes Assessor Primary Purpose: Prevention
Official Title:	A Prospective, Randomized, Double-blind, Placebo-controlled Study of Caffeine in the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Ambulatory Surgery Under General Anesthesia

Resource links provided by NLM:

MedlinePlus related topics: Anesthesia Caffeine Nausea and Vomiting

U.S. FDA Resources

Further study details as provided by Richard A. Steinbrook, Beth Israel Deaconess Medical Center:

Primary Outcome Measures:

Complete response (no PONV and no use of rescue medication) during the first 24 hours following anesthesia [ Time Frame: 1-24 hours post-operatively ]

Secondary Outcome Measures:

Nausea during the first 24 hours following anesthesia [ Time Frame: 1-24 hours post-operatively ]
Vomiting during the first 24 hours following anesthesia [ Time Frame: 1-24 hours post-operatively ]
Proportion of patients who use rescue medication during the first 24 hours following anesthesia [ Time Frame: 1-24 hours post-operatively ]
Post Anesthesia Care Unit (PACU) length of stay (Phase I, Phase II) [ Time Frame: hours post-operatively ]
Incidence of headache [ Time Frame: 1-24 hours post-operatively ]
Degree of fatigue [ Time Frame: 1-24 hours post-operatively ]
Overall satisfaction [ Time Frame: 1-24 hours post-operatively ]
Alertness [ Time Frame: 1-24 hours post-operatively ]
Admissions [ Time Frame: 1-24 hours post-operatively ]
Amount of pain medication required [ Time Frame: 1-24 hours post-operatively ]


Enrollment:	135
Study Start Date:	March 2005
Study Completion Date:	October 2005
Primary Completion Date:	October 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: I Saline placebo	Drug: Caffeine 500 mg IV

Detailed Description:

This is a prospective, randomized, double-blind, placebo-controlled study of caffeine, 500 mg, intravenously, in addition to standard anti-emetic prophylaxis, in the prevention of post-operative nausea and vomiting in patients undergoing ambulatory surgery under general anesthesia.

Consenting patients will be randomized to receive either a single dose of caffeine, 500 mg, or saline placebo, administered as a single IV dose approximately 15 minutes before emergence from anesthesia. All patients will receive our customary anti-emetic prophylaxis, determined by four major risk factors for PONV: female gender, nonsmoking status, history of PONV or motion sickness, and perioperative opioid use. Patients at low risk for PONV (no risk factors) will receive no prophylaxis; patients at moderate risk for PONV (1 or 2 risk factors) will receive dexamethasone 8 mg at induction plus dolasetron 12.5 mg approximately 15 min before the end of anesthesia; patients at high risk for PONV (3 or 4 risk factors) will receive the same treatment as those at moderate risk, plus additional prophylaxis at the discretion of the attending anesthesiologist (e.g., scopolamine patch, metoclopramide 10 mg IV, or other standard drugs).

Postoperatively, the presence of PONV will be recorded. If rescue medication is used, the amount and time of administration will be recorded. The length of stay in the PACU (Phase I and Phase II) will be recorded. Patients will be asked to report any headache, and to rate their nausea, pain, alertness, fatigue, and overall satisfaction in the PACU, and again by phone 24 hours postoperatively. Amount of pain medication utilized in the PACU will also be measured.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient having ambulatory surgery
Patient receiving general anesthesia

Exclusion Criteria:

Patient is not willing to sign informed consent
Patient does not speak or understand sufficient English

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00130026

Locations


United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215

Sponsors and Collaborators

Beth Israel Deaconess Medical Center

Investigators


Principal Investigator:	Richard A Steinbrook, MD	Beth Israel Deaconess Medical Center

More Information


Responsible Party:	Richard A. Steinbrook, Associate Professor of Anaesthesia, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:	NCT00130026 History of Changes
Other Study ID Numbers:	2004P000210
Study First Received:	August 11, 2005
Last Updated:	February 3, 2017

Additional relevant MeSH terms:


Nausea Vomiting Postoperative Nausea and Vomiting Signs and Symptoms, Digestive Signs and Symptoms Postoperative Complications Pathologic Processes Caffeine Central Nervous System Stimulants	Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 23, 2017